EGFR and neoplasm: The expression of CD73SC was more frequently observed in an early tumour stage (p = 0.037), PD-L1-negative tumours (p = 0.030), non-amplified EGFR tumours (p = 0.0018), and EGFR L858R-mutated tumours (p = 0.067) (Table 4).